Clinical Trials Logo

Retinitis Pigmentosa clinical trials

View clinical trials related to Retinitis Pigmentosa.

Filter by:

NCT ID: NCT03374657 Not yet recruiting - Clinical trials for Retinitis Pigmentosa

A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

Start date: April 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

CPK850 is a recombinant adeno-associated virus 8 (AAV8) vector containing the human RLBP1 gene. The purpose of this first-in-human study is to explore the maximum tolerated dose (MTD) of CPK850 as determined by the single ascending dose ranging portion of the study. This study will also evaluate the safety and potential efficacy of CPK850 on improving visual function in patients with decreased visual function from RLBP1 retinitis pigmentosa due to biallelic mutations in the RLBP1 gene.

NCT ID: NCT03368027 Completed - Clinical trials for Stress, Psychological

Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa

RCT
Start date: December 1, 2016
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy of cognitive - behavioral therapy for the control of psychopathological stress and the disease of people with Retinitis Pigmentosa (RP).

NCT ID: NCT03349242 Not yet recruiting - Clinical trials for Retinitis Pigmentosa

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

Start date: November 30, 2017
Phase: N/A
Study type: Observational

The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading to severe visual impairment. RP usually occurs as an isolated retinal disorder, but it may also be seen in association with systemic abnormalities.

NCT ID: NCT03328130 Recruiting - Clinical trials for Retinitis Pigmentosa

Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene

Start date: November 6, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a Phase I/II, monocentric, open-label, dose-ranging safety and efficacy gene therapy intervention by subretinal administration of AAV2/5-hPDE6B. At least twelve patients 18 years of age or older, within three consecutive cohorts of patients, will be recruited.

NCT ID: NCT03326336 Not yet recruiting - Clinical trials for Non-syndromic Retinitis Pigmentosa

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

PIONEER
Start date: January 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa

NCT ID: NCT03322930 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

Start date: October 1, 2017
Phase: N/A
Study type: Observational

A new fundus-guided microperimeter, the MP-3S, has been developed by Nidek, Inc. to track the fundus of the patient and present stimuli in specific anatomically-defined locations. Furthermore, this tracking means that exactly the same locations can be tested on subsequent (follow-up) visits. The investigators will use a method called two-color perimetry to map rod and cone sensitivity on this device. With this technique, the sensitivity difference (blue-red) to chromatic test stimuli can be used to determine whether rods, cones or both photoreceptor systems mediate the threshold at a given location in the macula.

NCT ID: NCT03319524 Active, not recruiting - Clinical trials for Retinitis Pigmentosa

Clinical and Genetic Testing of Patients With Usher Syndrome

Start date: May 17, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This study is aimed to characterize Russian population of Usher patients.

NCT ID: NCT03316560 Not yet recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations

Start date: January 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing a human RPGR-ORF15 gene (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations. Approximately 15 participants will be enrolled and 3 dose levels will be evaluated in a dose-escalation format.

NCT ID: NCT03314207 Not yet recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Start date: October 2017
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

NCT ID: NCT03281005 Recruiting - Clinical trials for Retinitis Pigmentosa

Development of Visual Function Evaluation Method

Start date: November 1, 2017
Phase: N/A
Study type: Observational

The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient